Table 3 Multivariable Cox proportional-hazards regression for overall survival.

From: A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients

Variable

 

HR

95%CI

p-value

Treatment

R-CHOP

1

  
 

R2CHOP

0.51

(0.26–1.00)

0.049

Sex

Male

1

  
 

Female

0.55

(0.29–1.06)

0.074

Age at incidence (years)

 

1.03

(1.00–1.06)

0.025

Ann Arbor stage

2

1

  
 

3

0.50

(0.15–1.61)

0.24

 

4

0.88

(0.29–2.66)

0.82

Extra-nodal localizations

None

1

  
 

1

0.55

(0.23–1.32)

0.18

 

2 or more

0.63

(0.27–1.47)

0.28

LDH

Within normal range

1

  
 

Elevated

3.96

(1.42–11.06)

0.009

WHO PS (grouped)

0

1

  
 

1

1.41

(0.68–2.93)

0.36

 

2 or 3

2.17

(0.98–4.79)

0.056

Rearrangement

Single hit

1

  
 

Double/triple hit

0.98

(0.49–1.94)

0.95

 

Missing BCL2/BCL6

0.49

(0.16–1.53)

0.22